Blueprint Medicines Co. (NASDAQ:BPMC) Stock Position Lifted by EFG Asset Management North America Corp.

EFG Asset Management North America Corp. lifted its position in Blueprint Medicines Co. (NASDAQ:BPMC) by 120.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 74,300 shares of the biotechnology company’s stock after acquiring an additional 40,611 shares during the quarter. Blueprint Medicines accounts for approximately 0.9% of EFG Asset Management North America Corp.’s holdings, making the stock its 20th largest position. EFG Asset Management North America Corp.’s holdings in Blueprint Medicines were worth $6,477,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Torray Investment Partners LLC grew its stake in Blueprint Medicines by 1.1% during the 4th quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company’s stock worth $1,439,000 after buying an additional 186 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Blueprint Medicines by 0.7% during the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock worth $3,259,000 after acquiring an additional 265 shares during the last quarter. Hillsdale Investment Management Inc. increased its holdings in shares of Blueprint Medicines by 0.6% in the 4th quarter. Hillsdale Investment Management Inc. now owns 50,830 shares of the biotechnology company’s stock worth $4,433,000 after acquiring an additional 310 shares during the period. Quarry LP bought a new stake in Blueprint Medicines in the 3rd quarter valued at about $32,000. Finally, Van ECK Associates Corp boosted its stake in Blueprint Medicines by 48.2% during the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 363 shares during the period.

Insider Activity

In other Blueprint Medicines news, CEO Kate Haviland sold 1,446 shares of Blueprint Medicines stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the transaction, the chief executive officer now owns 149,378 shares of the company’s stock, valued at $16,467,430.72. The trade was a 0.96 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Ariel Hurley sold 3,203 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total transaction of $296,661.86. Following the completion of the sale, the insider now directly owns 18,270 shares of the company’s stock, valued at $1,692,167.40. This trade represents a 14.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,334 shares of company stock worth $3,103,512 over the last quarter. Corporate insiders own 4.21% of the company’s stock.

Blueprint Medicines Price Performance

NASDAQ BPMC opened at $95.27 on Tuesday. Blueprint Medicines Co. has a 1 year low of $80.68 and a 1 year high of $121.90. The stock’s 50-day moving average price is $99.31 and its two-hundred day moving average price is $93.92. The company has a market cap of $6.09 billion, a PE ratio of -88.21 and a beta of 0.58. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. On average, analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Analyst Ratings Changes

BPMC has been the topic of a number of recent analyst reports. StockNews.com cut Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Monday, March 3rd. Wolfe Research began coverage on Blueprint Medicines in a research note on Tuesday, March 18th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. lifted their price objective on shares of Blueprint Medicines from $126.00 to $129.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Needham & Company LLC reiterated a “buy” rating and issued a $133.00 target price on shares of Blueprint Medicines in a research report on Thursday, February 13th. Finally, JMP Securities restated a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a research report on Friday, February 14th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $124.95.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.